4 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2043. from the record
Of the 8 now held by other companies, 8 name Servier Pharmaceuticals LLC as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2043
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Nov 2039 · Medium confidence
Cited by 9 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2039.
now held by Servier Pharmaceuticals LLC
Also notable
Ends Nov 2039 · High confidence
Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
now held by Servier Pharmaceuticals LLC
Also notable
Ends Nov 2039 · High confidence
The most cited patent in this portfolio, cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
now held by Servier Pharmaceuticals LLC
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Quinolinone Amide Compounds and Uses Thereof | 1 in force | to Mar 2044 |
| Quinazolinone Dione Compounds and Uses Thereof | 1 in force | to Mar 2044 |
| 1,4-Dihydroquinazolinone Compounds and Uses Thereof | 1 in force | to Sep 2043 |
| Pyridazinone Compounds for the Treatment of Neuromuscular Diseases | 1 in force | to Apr 2043 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,643,892 | Pyridazinone Compounds for the Treatment of Neuromuscular Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,509,431 | 1,4-Dihydroquinazolinone Compounds and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,448,369 | Quinolinone Amide Compounds and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,559,464 | Quinazolinone Dione Compounds and Uses Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 4: 8 patents in force now held by others · 18 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
7 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.